Chengjian Zhao

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Xiaoying Li · 2 shared papers, 2024–2025 · strength 0.42
   • Paper Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
2. Wanting Hou · 2 shared papers, 2024–2025 · strength 0.42
   • Paper Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
3. Zixing Huang · 2 shared papers, 2023–2025 · strength 0.31
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
   • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
4. Junjie Xiong · 2 shared papers, 2023–2025 · strength 0.31
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
   • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
5. Ke Cheng · 2 shared papers, 2023–2025 · strength 0.31
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
   • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
6. Rui Wang · 2 shared papers, 2023–2025 · strength 0.31
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
   • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
7. Dan Cao · 1 shared paper, 2024 · strength 0.26
   • Paper Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6↗
8. Chen Chang · 1 shared paper, 2025 · strength 0.16
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
9. Yi Zhang · 1 shared paper, 2025 · strength 0.16
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
10. Yi Cheng · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
11. Huanji Xu · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
12. Bole Tian · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
13. Dan Cao · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
14. Xiaorui Zhu · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
15. Qingqing Leng · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
16. Chenyan Zhang · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
17. Bo Chen · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
18. Wanrui Lv · 1 shared paper, 2023 · strength 0.14
    • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
19. Dan Cao · 1 shared paper, 2023 · strength 0.14
    • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
20. Bole Tian · 1 shared paper, 2023 · strength 0.14
    • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.